NASDAQ: ELTX
Elicio Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ELTX

Based on 2 analysts offering 12 month price targets for Elicio Therapeutics Inc

Min Forecast
$9.00+87.5%
Avg Forecast
$9.50+97.92%
Max Forecast
$10.00+108.33%

Should I buy or sell ELTX stock?

Based on 2 analysts offering ratings for Elicio Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ELTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ELTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ELTX stock forecasts and price targets.

ELTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-02
lockedlocked$00.00+00.00%2024-10-31

1 of 1

Forecast return on equity

Is ELTX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ELTX forecast to generate an efficient return on assets?

Company
N/A
Industry
36.07%

ELTX earnings per share forecast

What is ELTX's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$2.51
Avg 2 year Forecast
-$2.59

ELTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELTX$4.80$9.50+97.92%Strong Buy
VERU$0.52$4.00+664.82%Buy
IGMS$1.28$2.00+56.25%Hold
SGMT$2.39$29.00+1,113.39%Strong Buy
CRBP$6.30$53.25+745.24%Strong Buy

Elicio Therapeutics Stock Forecast FAQ

Is Elicio Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ELTX) stock is to Strong Buy ELTX stock.

Out of 2 analysts, 1 (50%) are recommending ELTX as a Strong Buy, 1 (50%) are recommending ELTX as a Buy, 0 (0%) are recommending ELTX as a Hold, 0 (0%) are recommending ELTX as a Sell, and 0 (0%) are recommending ELTX as a Strong Sell.

If you're new to stock investing, here's how to buy Elicio Therapeutics stock.

What is ELTX's earnings growth forecast for 2025-2026?

(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Elicio Therapeutics's earnings in 2025 is -$51,898,000.On average, 2 Wall Street analysts forecast ELTX's earnings for 2025 to be -$40,043,345, with the lowest ELTX earnings forecast at -$41,160,092, and the highest ELTX earnings forecast at -$38,926,599.

In 2026, ELTX is forecast to generate -$41,319,627 in earnings, with the lowest earnings forecast at -$41,319,627 and the highest earnings forecast at -$41,319,627.

What is ELTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ELTX) forecast ROE is N/A, which is considered weak.

What is ELTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ELTX price target, the average ELTX price target is $9.50, with the highest ELTX stock price forecast at $10.00 and the lowest ELTX stock price forecast at $9.00.

On average, Wall Street analysts predict that Elicio Therapeutics's share price could reach $9.50 by Apr 2, 2026. The average Elicio Therapeutics stock price prediction forecasts a potential upside of 97.92% from the current ELTX share price of $4.80.

What is ELTX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ELTX) Elicio Therapeutics's current Earnings Per Share (EPS) is -$4.25. On average, analysts forecast that ELTX's EPS will be -$2.51 for 2025, with the lowest EPS forecast at -$2.58, and the highest EPS forecast at -$2.44. In 2026, ELTX's EPS is forecast to hit -$2.59 (min: -$2.59, max: -$2.59).

What is ELTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ELTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 36.07%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.